New insights into immune-related adverse events in genitourinary cancers
The following is an interview with Dr Tanya Dorff, Associate Clinical [...]
Potential role for high dose IL2 in metastatic kidney cancer
The following is an interview with Dr Tanya Dorff, Associate Clinical [...]
First-line immunotherapy for metastatic kidney cancer
The following is a Practice Update interview with Dr Eric [...]
Managing adverse events for cancer immunotherapies
Immunotherapy treatments for cancer hold great promise, but also come [...]
Status of adjuvant therapy for the treatment of kidney cancer
Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an [...]
Tyrosine kinase inhibitors for kidney cancer: Past, present and future
In his keynote lecture at the American Society for Clinical Oncology Genitourinary [...]
The future of immuno-oncology in kidney cancer
In his keynote lecture at the American Society for Clinical [...]
Axitinib plus pembrolizumab combination shows promise for advanced kidney cancer
Data from a recent phase 1b study has shown that [...]
New first-line treatment option for advanced kidney cancer available on the NHS
Today, the National Institute for Health and Care Excellence (NICE) have recommended tivozanib (Fotivda) [...]
New drug shows promise in combination with cabozantinib for the treatment of advanced kidney cancer
Results from a phase 1 clinical trial looking at CB-839, [...]
